Literature DB >> 1546864

Eligibility for cholesterol referral in community-dwelling older adults. The Cardiovascular Health Study.

T A Manolio1, C D Furberg, P W Wahl, R P Tracy, N O Borhani, J M Gardin, L P Fried, D H O'Leary, L H Kuller.   

Abstract

OBJECTIVES: To assess the proportion of community-dwelling adults aged 65 years or older who are eligible for referral for lipoprotein analysis and intervention according to the National Cholesterol Education Program (NCEP) guidelines.
DESIGN: Cross-sectional study based on examinations and questionnaires collected in 1989 and 1990.
SETTING: Four communities in the U.S. in the Cardiovascular Health Study (CHS), a study of risk factors for heart disease and stroke in older adults. PARTICIPANTS: A sample of 4810 men and women ages 65 to 100 randomly selected and recruited from Health Care Financing Administration Medicare eligibility lists for the four communities; not institutionalized, not wheelchair-bound, not currently receiving therapy for cancer, not currently taking lipid-lowering medications, and not having eaten in the preceding 9 hours. MEASUREMENTS: Total cholesterol and lipoprotein analysis measured in all participants.
RESULTS: Total cholesterol levels were less than 5.17 mmol/L (200 mg/dL) in 37% of participants, 5.17 to 6.19 mmol/L (200 to 239 mg/dL) in 39%, and 6.20 mmol/L (240 mg/dL) or greater in 24%. Compared with their counterparts, older participants, especially those over 80 years of age, were more likely to have levels below 5.17 mmol/L, as were men, nonwhites, and those with coronary heart disease or two or more coronary heart disease risk factors (P less than 0.008 for all values). Based on this screening measurement, 2174 participants were eligible for lipoprotein analysis, 80% were eligible for dietary or drug therapy using NCEP guidelines. Overall, 46% of CHS participants were eligible for lipoprotein analysis and 36% for intervention by NCEP guidelines, based on a single cholesterol measurement.
CONCLUSION: A substantial proportion of older adults in this community sample were eligible for lipoprotein analysis and intervention. Prospective studies of elderly persons are needed to determine the risk for incident coronary heart disease according to NCEP classifications and the benefits of lipid-lowering treatments in persons in this age group so that intervention strategies may best be targeted to an appropriately high-risk group.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1546864     DOI: 10.7326/0003-4819-116-8-641

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  6 in total

Review 1.  Heart health in older adults. Import of heart disease and opportunities for maintaining cardiac health.

Authors:  L P Fried; R L McNamara; G L Burke; D S Siscovick
Journal:  West J Med       Date:  1997-10

2.  Relation of glycemic status with unrecognized MI and the subsequent risk of mortality: The Jackson Heart Study.

Authors:  R Brandon Stacey; Michael E Hall; Paul E Leaverton; Douglas D Schocken; Janice Zgibor
Journal:  Am J Prev Cardiol       Date:  2022-05-10

3.  Subclinical hypothyroidism and the risk of hypercholesterolemia.

Authors:  William J Hueston; William S Pearson
Journal:  Ann Fam Med       Date:  2004 Jul-Aug       Impact factor: 5.166

Review 4.  Management of older adults with hypercholesterolaemia.

Authors:  J T Pacala; P E McBride; S L Gray
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

5.  Abnormal Fasting Glucose Increases Risk of Unrecognized Myocardial Infarctions in an Elderly Cohort.

Authors:  Richard Brandon Stacey; Janice Zgibor; Paul E Leaverton; Douglas D Schocken; Jennifer A Peregoy; Mary F Lyles; Alain G Bertoni; Gregory L Burke
Journal:  J Am Geriatr Soc       Date:  2018-10-09       Impact factor: 5.562

6.  Hypercholesterolemia and its correlates in Taiwanese elderly people.

Authors:  C C Lin; T C Li; S W Lai; C I Li; C K Tan; K C Ng; M M Lai; C S Liu
Journal:  Yale J Biol Med       Date:  1999 Nov-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.